Body mass index and gonadotropin hormones (LH & FSH) associate with clinical symptoms among women with polycystic ovary syndrome

Seddigheh Esmaeilzadeh, Maryam Ghanbari Andarieh, Reza Ghadimi, Mouloud Agajani Delavar, Seddigheh Esmaeilzadeh, Maryam Ghanbari Andarieh, Reza Ghadimi, Mouloud Agajani Delavar

Abstract

To evaluate the relevance of body mass index (BMI), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and LH/FSH ratio with clinical symptoms in polycystic ovary syndrome (PCOS) women.

Methods: We reviewed the medical records of all women visited in the PCOS Clinic of Babol (Iran) from 2008 to 2012. A retrospective cross-sectional study was conducted on 175 PCOS women; aged 18-38 years diagnosed based on the Rotterdam criteria. Among the PCOs women, the prevalence of oligomenorrhea, acne, and hirsutism were found to be 92.0%, 31.4%, and 78.9%, respectively. Positive finding of polycystic ovaries was observed in 89.1% of PCOS women with by using sonography. A total of 69.2% overweight/obesity patients had polycystic ovary morphology on ultrasound image. Compared with non- overweight/obesity, the adjusted OR of PCOS women for sonographic view of polycystic ovaries was 4.33 (95% CI, 1.42-13.15, p=0.001), Nevertheless, the adjusted odds ratio (OR) showed no significant associations between LH, FSH, and LH/FSH ratio with clinical symptoms in these women. The findings of this study indicated that the overweight/obese women with PCOS are at an increased risk for sonographic view of polycystic ovaries. Therefore, it is suggested that successful weight loss is the most effective method of restoring ovulation, menstruation that should be used as major advice in obese PCOS patients.

References

    1. Adams J, Franks S, Polson D. W, Mason H. D, Abdulwahid N, Tucker M, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet. 1985:21–28. 2(8469-70), 1375-1379.
    1. Alnakash A. H, Al-Tae’e N. K. Polycystic ovarian syndrome: the correlation between the LH/FSH ratio and disease manifestations. Middle East Fertility Society Journal. 2007;12(1):35–40.
    1. Banaszewska B, Spaczynski R. Z, Pelesz M, Pawelczyk L. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia. Rocz Akad Med Bialymst. 2003;48:131–134.
    1. Boyle J. A, Cunningham J, O’Dea K, Dunbar T, Norman R. J. Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. Med J Aust. 2012;196(1):62–16.
    1. Boyle J, Teede H. J. Polycystic ovary syndrome - an update. Aust Fam Physician. 2012;41(10):752–756.
    1. Diamanti-Kandarakis E, Kandarakis H, Legro R. S. The role of genes and environment in the etiology of PCOS. Endocrine. 2006;30(1):19–26. .
    1. Dinka P. B, Lana Š, Zrinka B. M, Iva T. Hyperandrogenemia Association with Acne and Hirsutism Severity in Croatian Women with Polycystic Ovary Syndrome. Acta dermatovenerologica Croatica. 2013;21(2)
    1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774–800.
    1. Fakhoury H, Tamim H, Ferwana M, Siddiqui I. A, Adham M, Tamimi W. Age and BMI Adjusted Comparison of Reproductive Hormones in PCOS. J Family Med Prim Care. 2012;1(2):132–136. .
    1. Insler V, Shoham Z, Barash A, Koistinen R, Seppala M, Hen M, et al. Polycystic ovaries in non-obese and obese patients: possible pathophysiological mechanism based on new interpretation of facts and findings. Hum Reprod. Mar. 1993;8(3):379–384.
    1. Kiddy D. S, Sharp P. S, White D. M, Scanlon M. F, Mason H. D, Bray C. S, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 1990;32(2):213–20. .
    1. Legro R. S, Arslanian S. A, Ehrmann D. A, Hoeger K. M, Murad M. H, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592. .
    1. Loverro G, De Pergola G, Di Naro E, Tartagni M, Lavopa C, Caringella A. M. Predictive value of ovarian stroma measurement for cardiovascular risk in polycyctic ovary syndrome: a case control study. J Ovarian Res. 2010;3:25. .
    1. March W. A, Moore V. M, Willson K. J, Phillips D. I, Norman R. J, Davies M. J. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–551. .
    1. Moran L. J, Ko H, Misso M, Marsh K, Noakes M, Talbot M, et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. Hum Reprod Update. 2013;19(5):432. .
    1. Panidis D, Tziomalos K, Papadakis E, Chatzis P, Kandaraki E. A, Tsourdi E. A, et al. The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome. Eur J Endocrinol. 2013;168(6):871–87. .
    1. Pasquali R, Vicennati V, Gambineri A. Influence of weight and distribution of adipose tissue in functional hyperandrogenism. Contracept Fertil Sex. 1998;26(5):372–375.
    1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2012;81(1):19–25.
    1. Sharquie K. E, Al-Bayatti A. A, Al-Ajeel A. I, Al-Bahar A. J, Al-Nuaimy A. A. Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome. Saudi Med J. 2007;28(7):1039–1043.
    1. Takahashi K, Okada M, Ozaki T, Uchida A, Yamasaki H, Kitao M. Transvaginal ultrasonographic morphology in polycystic ovarian syndrome. Gynecol Obstet Invest. 1995;39(3):201–206. .
    1. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41. .
    1. Wijeyaratne C. N, Jayasinghe A, de Silva D. G, Parkes A. B, Lazarus J. H, Premawardhana L. D. Iodine prophylaxis, goitre and thyroid autoimmunity in Sri Lanka. Ceylon Med J. 2005;50(1):20–23.
    1. Yanira L. P, Serene S. S, Yarisie J, Anne E, Sabrina G, Janet E. H. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome. Investigation of hypothalamic and pituitary contributions. J Clin Endorin & Metabol. 2006;91(4):1309–1316. .

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever